NCT05792826 is a NA clinical trial of BSZY Cream in Atopic Dermatitis of Face (Diagnosis), sponsored by Shanghai Yueyang Integrated Medicine Hospital.

Who is sponsoring NCT05792826?

NCT05792826 is sponsored by Shanghai Yueyang Integrated Medicine Hospital.

What drugs are being tested in NCT05792826?

Interventions in NCT05792826: BSZY Cream, emulsion matrix.

What condition does NCT05792826 study?

NCT05792826 studies Atopic Dermatitis of Face (Diagnosis).

Is NCT05792826 still recruiting?

NCT05792826 is currently status unknown. Last updated 31 March 2023.

Last reviewed 2023-03-31 · How we verify

NCT05792826

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study of BSZY Cream Intervention to Relieve Atopic Facial Dermatitis

Status unknown NA Last updated 31 March 2023

What this trial tests

NA trial testing BSZY Cream in Atopic Dermatitis of Face (Diagnosis) in 130 participants. Status unknown.

Timeline

1 April 2023

Primary endpoint
30 June 2024

30 June 2024

Quick facts

Lead sponsor	Shanghai Yueyang Integrated Medicine Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	130
Start date	1 April 2023
Primary completion	30 June 2024
Estimated completion	30 June 2024
Sites	1 location across China

Drugs / interventions tested

BSZY Cream
emulsion matrix

Conditions studied

Atopic Dermatitis of Face (Diagnosis) — all drugs for Atopic Dermatitis of Face (Diagnosis) →

Sponsor

Shanghai Yueyang Integrated Medicine Hospital

Who can join

18 and older, any sex, with Atopic Dermatitis of Face (Diagnosis). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized double-blind controlled trial will be conducted in conducted in the Department of Dermatology at the Yueyang Hospital of Integrated Traditional Chinese and Western Medicine in China.An estimated 130 participants will be recruited and randomly assigned to receive BSZY Cream or emulsion matrix group in a l:l ratio using SPSS 25.0 software.Application is twice a day, morning and evening, for four weeks.The primary outcome will be the SCORAD scale.The secondary outcomes included clinical dermatologist assessment forms, patient self-assessment questionnaires, and safety indicators.The adverse events will be recorded for safety evaluation. All data in the study will be analyzed using the SPSS 25.0 statistical software package.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Topical anti-inflammatory treatments for eczema: network meta-analysis.
Lax SJ, Van Vogt E, Candy B, Steele L, et al · · 2024 · cited 22× · PMID 39105474 · DOI 10.1002/14651858.cd015064.pub2
Efficacy and safety of BSZY cream for mild-to-moderate atopic facial dermatitis: protocol of a randomised, double-blind, controlled trial.
Wang P, Wei X, Cheng L, Guo D, et al · · 2025 · PMID 40122554 · DOI 10.1136/bmjopen-2024-087149

Verify or expand the search:

Other Shanghai Yueyang Integrated Medicine Hospital trials

Trials by the same sponsor.

NCT07434076 — Cross-Sectional Study for an Ocular Imaging-Based Predictive Model of Inflammatory Skin Diseases Grounded in Traditional · not yet recruiting
NCT07351448 — Research on the Extraction of Tongue and Facial Diagnosis Features of Psoriasis Vulgaris in Traditional Chinese Medicine · not yet recruiting
NCT07003386 — Exploration of the Efficacy and Mechanism of Galantamine (an Extract From Lycoris Aurea) in Treating Ischemic Stroke · Phase 2, PHASE3 · recruiting
NCT06922565 — Efficacy of Acupuncture in the Treatment of Moderate-to-severe Atopic Dermatitis · NA · not yet recruiting
NCT06790940 — Construction of a Psoriasis and Psoriatic Arthritis Diagnostic Model Based on Multidimensional Nail Information · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05792826 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Yueyang Integrated Medicine Hospital
Last refreshed: 31 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05792826.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing